Your browser doesn't support javascript.
loading
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
Zinter, Matt S; Dvorak, Christopher C; Mayday, Madeline Y; Reyes, Gustavo; Simon, Miriam R; Pearce, Emma M; Kim, Hanna; Shaw, Peter J; Rowan, Courtney M; Auletta, Jeffrey J; Martin, Paul L; Godder, Kamar; Duncan, Christine N; Lalefar, Nahal R; Kreml, Erin M; Hume, Janet R; Abdel-Azim, Hisham; Hurley, Caitlin; Cuvelier, Geoffrey D E; Keating, Amy K; Qayed, Muna; Killinger, James S; Fitzgerald, Julie C; Hanna, Rabi; Mahadeo, Kris M; Quigg, Troy C; Satwani, Prakash; Castillo, Paul; Gertz, Shira J; Moore, Theodore B; Hanisch, Benjamin; Abdel-Mageed, Aly; Phelan, Rachel; Davis, Dereck B; Hudspeth, Michelle P; Yanik, Greg A; Pulsipher, Michael A; Sulaiman, Imran; Segal, Leopoldo N; Versluys, Birgitta A; Lindemans, Caroline A; Boelens, Jaap J; DeRisi, Joseph L.
Afiliação
  • Zinter MS; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. matt.zinter@ucsf.edu.
  • Dvorak CC; Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. matt.zinter@ucsf.edu.
  • Mayday MY; Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Reyes G; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Simon MR; Departments of Laboratory Medicine and Pathology, Yale School of Medicine, New Haven, CT, USA.
  • Pearce EM; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Kim H; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Shaw PJ; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Rowan CM; Division of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Auletta JJ; The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Martin PL; Department of Pediatrics, Division of Critical Care Medicine, Indiana University, Indianapolis, IN, USA.
  • Godder K; Hematology/Oncology/BMT and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH, USA.
  • Duncan CN; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA.
  • Lalefar NR; Division of Pediatric and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Kreml EM; Cancer and Blood Disorders Center, Nicklaus Children's Hospital, Miami, FL, USA.
  • Hume JR; Division of Pediatric Oncology Harvard Medical School Department of Pediatrics, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
  • Abdel-Azim H; Division of Pediatric Hematology/Oncology, Benioff Children's Hospital Oakland, University of California, San Francisco, Oakland, CA, USA.
  • Hurley C; Department of Child Health, Division of Critical Care Medicine, University of Arizona, Phoenix, AZ, USA.
  • Cuvelier GDE; Department of Pediatrics, Division of Critical Care Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Keating AK; Department of Pediatrics, Division of Hematology/Oncology and Transplant and Cell Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Qayed M; Loma Linda University School of Medicine, Cancer Center, Children Hospital and Medical Center, Loma Linda, CA, USA.
  • Killinger JS; Department of Pediatric Medicine, Division of Critical Care, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Fitzgerald JC; CancerCare Manitoba, Manitoba Blood and Marrow Transplant Program, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Hanna R; Division of Pediatric Oncology Harvard Medical School Department of Pediatrics, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
  • Mahadeo KM; Center for Cancer and Blood Disorders, Children's Hospital Colorado and University of Colorado, Aurora, CO, USA.
  • Quigg TC; Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA.
  • Satwani P; Department of Pediatrics, Division of Pediatric Critical Care, Weill Cornell Medicine, New York, NY, USA.
  • Castillo P; Department of Anesthesiology and Critical Care, Perelman School of Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
  • Gertz SJ; Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Moore TB; Division of Pediatric and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Hanisch B; Department of Pediatrics, Division of Hematology/Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Abdel-Mageed A; Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute, Methodist Children's Hospital, San Antonio, TX, USA.
  • Phelan R; Section of Pediatric BMT and Cellular Therapy, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
  • Davis DB; Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University, New York, NY, USA.
  • Hudspeth MP; UF Health Shands Children's Hospital, University of Florida, Gainesville, FL, USA.
  • Yanik GA; Department of Pediatrics, Division of Critical Care Medicine, Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Pulsipher MA; Department of Pediatrics, Division of Critical Care Medicine, St. Barnabas Medical Center, Livingston, NJ, USA.
  • Sulaiman I; Department of Pediatric Hematology-Oncology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, USA.
  • Segal LN; Department of Pediatrics, Division of Infectious Diseases, Children's National Hospital, Washington DC, USA.
  • Versluys BA; Section of Pediatric BMT and Cellular Therapy, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
  • Lindemans CA; Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Boelens JJ; Department of Pediatrics, Hematology/Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
  • DeRisi JL; Adult and Pediatric Blood & Marrow Transplantation, Pediatric Hematology/Oncology, Medical University of South Carolina Children's Hospital/Hollings Cancer Center, Charleston, SC, USA.
Nat Med ; 30(7): 1982-1993, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38783139
ABSTRACT
Hematopoietic cell transplantation (HCT) uses cytotoxic chemotherapy and/or radiation followed by intravenous infusion of stem cells to cure malignancies, bone marrow failure and inborn errors of immunity, hemoglobin and metabolism. Lung injury is a known complication of the process, due in part to disruption in the pulmonary microenvironment by insults such as infection, alloreactive inflammation and cellular toxicity. How microorganisms, immunity and the respiratory epithelium interact to contribute to lung injury is uncertain, limiting the development of prevention and treatment strategies. Here we used 278 bronchoalveolar lavage (BAL) fluid samples to study the lung microenvironment in 229 pediatric patients who have undergone HCT treated at 32 children's hospitals between 2014 and 2022. By leveraging paired microbiome and human gene expression data, we identified high-risk BAL compositions associated with in-hospital mortality (P = 0.007). Disadvantageous profiles included bacterial overgrowth with neutrophilic inflammation, microbiome contraction with epithelial fibroproliferation and profound commensal depletion with viral and staphylococcal enrichment, lymphocytic activation and cellular injury, and were replicated in an independent cohort from the Netherlands (P = 0.022). In addition, a broad array of previously occult pathogens was identified, as well as a strong link between antibiotic exposure, commensal bacterial depletion and enrichment of viruses and fungi. Together these lung-immune system-microorganism interactions clarify the important drivers of fatal lung injury in pediatric patients who have undergone HCT. Further investigation is needed to determine how personalized interpretation of heterogeneous pulmonary microenvironments may be used to improve pediatric HCT outcomes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Líquido da Lavagem Broncoalveolar / Transplante de Células-Tronco Hematopoéticas / Lesão Pulmonar / Disbiose Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Líquido da Lavagem Broncoalveolar / Transplante de Células-Tronco Hematopoéticas / Lesão Pulmonar / Disbiose Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article